CatalystMarker
← board

SDGR

distress 0/10 · well-funded / low risk
$15.20+1%today-34% from 52w high
schrodinger.com850 employeesFounded 1990New York, NYHealth Information Services
Revenue
$59M
Liquidity
$399M
Runway
2.8 yrs
Shares 1y

Price & events

-12.3% over 6M
$11.07$14.23$17.39Jan 26Apr 26Jul 265.3Mrating: Morgan Stanley: Equal-Weight (2026-05-14)rating: Keybanc: Overweight (2026-04-08)rating: UBS: Neutral (2026-03-17)
CatalystRating changeDilutionFinancingdashed = today
+1.1%
1D
-2.6%
1W
+1.1%
1M
+33.2%
3M
-7.4%
6M
-34.0%
1Y
-33.0%
2Y
-78.2%
5Y
-80.9%
All

Overview

Volume
56.13K
52 Week Range
$11.07 – $23.03
Float Shares
57.65M
Short %
25.09%
% Held by Insiders
3.01%
% Held by Institutions
98.22%
RVOL
0.05x
Beta
1.62

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: · 0 offerings/1y · 0 PIPEs
  • 2024-11-13SC 13Gstrategic_stake
  • 2024-11-128-Kmaterial_agreement
  • 2024-09-128-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $21 (+35% upside) · 7 analysts
  • 2026-05-14Morgan StanleyEqual-Weight
  • 2026-04-08KeybancOverweight
  • 2026-03-17UBSNeutral
  • 2026-01-08KeybancOverweight
  • 2026-01-08TD CowenBuy
  • 2026-01-07UBSNeutral

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.